Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia.

The Journal of clinical psychiatry

Volumn 68, Issue 2, 2007, Pages

  Rosenheck, Robert A ^a   Lieberman, Jeffrey A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; ECONOMICS; HEALTH CARE POLICY; HUMAN; MANAGEMENT; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; COST CONTROL; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH POLICY; HUMANS; POLICY MAKING; SCHIZOPHRENIA; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 33847761075     PISSN: None     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/jcp.0207e05     Document Type: Article

References (0)